11h agoLongevity startup NewLimit raises $435 million Series C to start human clinical trials next yearBreakthrough cellular reprogramming results pulled the trial timeline forward.SentimentSentimentPos89.6%Neg10.4%Many users celebrated NewLimit's $435M Series C raise for longevity trials as exciting progress and a win for humanity, while a few criticized the logo or questioned biotech timelines.77 comments with sentiment. View comments.